市場調査レポート

ブラジルの医薬品市場

The Pharmaceutical Market: Brazil

発行 Espicom Business Intelligence 商品コード 242139
出版日 ページ情報 英文 192 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
ブラジルの医薬品市場 The Pharmaceutical Market: Brazil
出版日: 2013年01月31日 ページ情報: 英文 192 Pages
担当者のコメント
このシリーズは、他にも調査対象国がございます。詳細はお問合せください。
概要

当レポートでは、ブラジルの医薬品市場について、市場全体の動向と法規制、 医薬品流通チャネルなどを分析し、OTC医薬品、ジェネリック医薬品、 バイオ医薬品・バイオシミラーなどのセグメント別の動向、市場の機会と課題などを併せ、 概略下記の構成でお届けいたします。

目次

エグゼクティブサマリー

  • スナップショット: Espicom の戦略的分析
  • スナップショット: 主要データ予測

マクロ環境

  • 政治環境
  • 経済環境
  • 法環境
  • 強制実施権; Efavirenz
  • 人口統計

疫学

  • 病気の負荷
  • 羅漢率

ヘルスケア - 保健統計付

  • 組織・機構
  • 保険
  • 医療費
  • サービス
  • 労働力

規制関連情報

  • 国際的な進展状況
  • 国内規制
  • 市場登録
  • 輸入
  • 臨床試験
  • 標識付けとパッケージング
  • 品質管理
  • 広告・宣伝
  • トレーサビリティ
  • 薬事規制

価格決定および償還

  • 償還

流通チャネル

  • 医薬品 卸売り
  • 医薬品 小売

    市場分析

    • 規模
    • 製品開発
    • 製造
    • 貿易

    競合状況

    • 事業者団体
    • 見本市
    • 企業情報

    OTC 医薬品

    • 市場規模
    • 競合状況

    ジェネリック医薬品

    • 規制
    • 市場規模
    • 競合状況

生物製剤/バイオシミラー

  • マクロ環境
  • 規制
  • 市場
  • 競合状況

結び: 機会と課題

  • Espicom の戦略的分析
    • マクロ環境
    • 疫学
    • ヘルスケア
    • 規制関連情報
    • 価格決定および償還
    • 流通チャネル
    • 市場
    • 競合状況
    • OTC 医薬品
    • ジェネリック医薬品
    • 生物製剤/バイオシミラー
  • レーダー解析
  • SWOT分析

関係各機関・組織一覧

  • 競合状況
  • 政府組織
  • 事業者団体

図表


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL

The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to its large market size and strong domestic demand for innovative, high-tech products. The government i s increasing ly invest ing in the healthcare sector and pharmaceutical industry to reduce the financial burden of diseases , and the country's private healthcare sectors provide opportunities for foreign companies. However, the increasing d rug rebate level has significantly undermined the profits recorded by generic drugmakers. The more aggressive government techonology transfer deals with multinationals as well as the drug approval delays due to bureaucracy and staff shortages at ANVISA have also dampened multinationals' revenue-generating opportunities

Headline Expenditure Projections

Pharmaceuticals: BRL48.10bn (US$28.72bn) in 2011 to BRL51.76bn (US$25.88bn) in 2012; +7.6% in local currency terms and -9.9% in US dollars terms. Forecast down from Q 4 12 due to less optimistic industry projections.

Healthcare: BRL378.63bn (US$226.04bn) in 2011 to BRL416.46bn (US$208.23bn) in 2012; +10.0% in local currency terms and -7.9% in US dollars. Forecast upwards from Q 4 12 due to more optimistic historical data.

Medical D evices: BRL7.45bn (US$4.45bn) in 2011 to BRL8.31bn (US$4.15bn) in 2012; +11.5% in local currency terms and -6.6%% in US dollars terms. Forecast revised down wards from Q 4 12 due to analyst intervention.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Table of Contents

Executive Summary

SWOT Analysis

  • Brazil Pharmaceuticals And Healthcare Industry SWOT
  • Brazil Political SWOT
  • Brazil Economic SWOT
  • Brazil Business Environment SWOT

Pharmaceutical Risk/Reward Ratings

  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113

Brazil - Market Summary

Regulatory Regime

  • Intellectual Property Environment
  • Counterfeits
  • Compulsory Licensing
  • Pricing Regime
  • Reimbursement Regime
  • Table: Medicines In The Partnership Deals
  • OTC Regulations
  • Advertising

Industry Developments

  • Epidemiology
  • Healthcare Sector
  • Healthcare Sector Funding
  • Research And Development
  • Biotechnology
  • Clinical Trials
  • Medical Devices Market
  • Medical Device Industry - Recent Developments
  • Medical Device Distribution

Industry Forecast Scenario

  • Overall Market Forecast
  • Table: Brazil Pharmaceutical Sales, Historical Data And Forecasts
  • Key Growth Factors - Industry
  • Table: Brazil Healthcare Expenditure Trends, Historical Data And Forecasts
  • Table: Brazil Government Healthcare Expenditure Trends, Historical Data And Forecasts
  • Table: Brazil Private Healthcare Expenditure Trends, Historical Data And Forecasts
  • Key Growth Factors - Macroeconomic
  • Table: Brazil - Economic Activity
  • Prescription Drug Market Forecast
  • Table: Brazil Prescription Drug Market Indicators, Historical Data And Forecasts
  • Patented Drug Market Forecast
  • Table: Brazil Patented Drug Market Indicators, Historical Data And Forecasts
  • Generic Drug Market Forecast
  • Table: Brazil Generics Drug Market Indicators, Historical Data And Forecasts
  • Table: Cumulative Active Ingredients, Registrations & Presentations Of Generics, 2000-April 2012
  • Table: Top-12 Leading Brands Losing Patent, 2012
  • OTC Medicine Market Forecast
  • Table: Brazil Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
  • Pharmaceutical Trade Forecast
  • Table: Brazil Pharmaceutical Trade Data And Forecasts (US$mn)
  • Table: Brazil Pharmaceutical Trade Data And Forecasts (BRLmn)
  • Medical Device Market Forecast
  • Table: Brazil Medical Device Market Indicators, Historical Data And Forecasts
  • Other Healthcare Data
  • Key Risks To BMI's Forecast Scenario

Competitive Landscape

  • Pharmaceutical Industry
  • Top 20 Pharmaceutical Companies In Brazil By Sales In 2010
  • Innovative Drugmakers
  • Innovative Drugmakers - Recent Developments
  • Table: Members of ABIMIP, 2011
  • Table: Members Of INTERFARMA, 2011
  • Generic Drugmakers
  • Table: Members Of ALANAC, 2011
  • Table: Members Of ALFOB, 2011
  • Members Of Pró-Genéricos, 2011
  • Hypermarcas' Major Acquisitions, 2005-11
  • Table: Hypermarcas' Net Sales By Division, 2009-10 (R$mn)
  • OTC Sector
  • Pharmaceutical Distribution Sector
  • Table: Members Of ABAFARMA, 2012
  • Members Of ABRADILAN, 2012
  • Profarma's Net & Gross Sales, 2005-11 (R$mn)
  • Table: Profarma's Distribution Centres By Location, 2012
  • Santa Cruz's Distribution Centres By
  • Pharmaceutical Retail Sector
  • Table: ABRAFARMA's Ranking Of Pharmacy Chains By Sales, 2010-11
  • Table: ABRAFARMA's Ranking Of Pharmacy Chains By Number Of Outlets, 2010-11
  • Table: ABRAFARMA's Financial Indicators, 2008-11
  • Table: Members Of ABRAFARMA, 2012
  • Table: Members Of ASSIFARMA, 2012
  • Table: Members Of FEBRAFAR By Region, 2012
  • Table: Pague Menos' Gross Sales, 2000-11
  • Table: RaiaDrogasil's Gross Sales, 2001-11 (R$mn)
  • Table: RaiaDrogasil's Number Of Pharmacies, 2001-12

Company Profiles

  • Aché/Biosintética
  • EMS Sigma
  • Eurofarma
  • Medley
  • Cristália
  • Sanofi
  • Pfizer
  • Merck & Co
  • Novartis
  • GlaxoSmithKline
  • Roche

Demographic Outlook

  • Table: Brazil's Population By Age Group, 1990-2020 ('000)
  • Table: Brazil's Population By Age Group, 1990-2020 (% of total)
  • Table: Brazil's Key Population Ratios, 1990-2020
  • Table: Brazil's Rural And Urban Population, 1990-2020

Glossary

BMI Methodology

  • How We Generate Our Pharmaceutical Industry Forecasts
  • Pharmaceuticals Business Environment Ratings
  • Risk/Reward Ratings Methodology
  • Ratings Overview
  • Table: Pharmaceutical Business Environment Indicators
  • Weighting
  • Table: Weighting Of Components
  • Sources
Back to Top